Exelixis Above Price Target; Estimate Gap Narrows Fast
Exelixis earned its fourth consecutive earnings beat, with $0.94 EPS surpassing the $0.904 consensus, but the beat margin compressed to 4.4 percent from 16.1 percent three quarters ago as analyst esti
EXEL Runs Past Analyst Price Target on Earnings Streak
NEW YORK, November 3 —
Four straight quarterly earnings beats have not resolved the central question around Exelixis, Inc. (EXEL). The stock trades at $70.13, above the Wall Street consensus analyst price target of $59.79, while 15.3% of the float remains sold short, a bearish position that has refused to close through every upside surprise.
- Gross margin 96.3%; $759 million free cash flow; $890 million in cash against $160 million in total debt.
- Beat margin compressed from 16.1% three quarters ago to 4.4%; analyst estimates have closed the gap.
The Compression Problem
Exelixis, Inc. makes CABOMETYX (cabozantinib tablets), approved for advanced renal cell carcinoma, and COMETRIQ for medullary thyroid cancer, drugs built on a kinase inhibitor targeting MET, AXL, and VEGF receptors. Four consecutive earnings beats, from a high of 16.1% above consensus three quarters ago to below 5% in the most recent quarter per the October 29 8-K, show a company whose performance the Street has increasingly anticipated. A stock already trading above analyst consensus needs fresh upside catalysts, not continued confirmation of what models now expect.
The Economics the Bears Face
What makes the 15.3% short position striking is the balance sheet it must contend with. Against $160 million in total debt, Exelixis holds $890 million in cash. Director Mary C. Beckerle sold 9,812 shares at $53.66 per the Form 4 filing; at $70.13 today, that sale sits more than $16 per share below the current price.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| EXEL | $17.1B | 16.4x | +82.3% |
| INCY | $24.5B | 13.9x | +18.5% |
| BMRN | $11.1B | 9.0x | +10.7% |
| ACAD | $3.5B | 22.2x | -8.0% |
| NBIX | $14.8B | 12.1x | +2.9% |
| VRTX | $140.1B | 27.1x | +31.2% |
What the Next Print Decides
The next quarterly report tests whether analyst estimates have fully converged or Exelixis can reopen a gap. The beat margin stands at 4.4%, and whether it expands or compresses from there is the variable that justifies or undercuts the stock's premium over the $59.79 analyst consensus target. Bristol-Myers Squibb's Phase 3 data, showing 38% disease-progression risk reduction in metastatic breast cancer with an ADC, shows how fast the competitive market is shifting for Exelixis's own zanzalintinib and ADC pipeline. Model the implied growth at the DCF calculator; run the free Exelixis, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Did Exelixis beat earnings estimates?
Yes, Exelixis beat consensus for the fourth consecutive quarter. The most recent quarter reported $0.94 EPS versus consensus of $0.904, while revenue of $2.50 billion exceeded expectations and grew 10.2% year-over-year. However, the beat margin compressed from 16.1% three quarters ago to 4.4%, indicating analyst estimates are converging on actual results.
What is Exelixis stock trading at?
Exelixis stock trades at $70.13, above the Wall Street consensus price target of $59.79. The stock has benefited from four consecutive quarterly earnings beats, though analyst estimates have increasingly converged on actual results.
What products does Exelixis manufacture?
Exelixis makes CABOMETYX (cabozantinib tablets), approved for advanced renal cell carcinoma, and COMETRIQ for medullary thyroid cancer. Both drugs are built on a kinase inhibitor targeting MET, AXL, and VEGF receptors.
What is Exelixis's financial position?
Exelixis holds $890 million in cash against $160 million in total debt. The company generated $759 million in free cash flow with gross margins of 96.3% on CABOMETYX, which includes commercial sales and royalties from partners including Ipsen Pharma and Bristol-Myers Squibb.
What's the next catalyst for Exelixis?
The next quarterly report tests whether analyst estimates have fully converged or if Exelixis can reopen a gap. The beat margin stands at 4.4%; whether it expands or compresses will determine if the stock's premium over the consensus target is justified.
Exelixis filed its most recent earnings 8-K on October 29, 2026, extending a four-quarter streak of beating consensus estimates — yet the stock now trades at $70.13, above the Wall Street consensus analyst price target of $59.79, while 15.3% of the float remains sold short.